COMPANY

BIND Russia

English | Russian

At BIND Biosciences we seek to make significant improvements in patients' lives and treat life-threatening diseases with a powerful new class of targeted therapeutics called Accurins™.

Our world-class team of scientists, managers and investors is positioning BIND as a leader in the development of targeted therapeutics. We are very pleased to expand our business in Russia through the establishment of BIND RUS. We seek to recruit those who share our passion and are inspired by the potential of our technology to make a difference for patients.

BIND RUS is a wholly owned subsidiary of BIND Biosciences Inc. In close collaboration with BIND Biosciences, BIND RUS will create and develop new best-in-class therapeutics.

We are recruiting highly motivated and experienced individuals with backgrounds in polymer chemistry, pharmacology, pharmaceutical sciences and engineering, or related fields. Our new employees will work in modern laboratories and be in close contact with BIND’s staff in Boston. Senior staff will be trained in Boston and the entire team will have the opportunity to learn from leading experts in the fields of medicinal nanotechnology and targeted therapeutics.

The establishment of BIND RUS supports the Russian Government’s Pharma 2020 policy to support local companies to develop and produce innovative medicines to reduce imports and provide access to the latest therapies for the benefit of patients in Russia.

Russian and international companies, who are interested in collaborating with us, are welcome to contact us at (info@bindbio.com).

BIND is a clinical-stage biopharmaceutical company developing a new class of highly selective targeted therapeutics called Accurins™. We seek to significantly improve patients' lives and treat disease in a powerful new way by designing Accurins to selectively accumulate at the site of disease, dramatically enhancing efficacy while minimizing effects on healthy tissues.

Accurins hold extraordinary potential for developing best-in-class drugs that improve patient outcomes across a broad range of disease areas. We are using our Medicinal Nanoengineering® platform to create a pipeline of proprietary Accurins that have demonstrated unique properties for targeting disease. In addition, we are developing Accurins in collaboration with pharmaceutical and biotechnology partners to enable promising pipeline candidates to achieve their full potential with optimized properties and to transform the performance of important existing drug products.

Our company was founded in 2006 in Boston, MA, USA based on technology first conceived at MIT and Harvard.